NUTM1 and sarcoma: It is estimated that CIC‐DUX4 fusions can be observed in approximately 60% of CIC‐rearranged sarcomas, with lower incidence of others fusion partner such as FOXO4 and NUTM1. 9, 10 Chang et al.7 demonstrated that the current NanoString panel identified one CIC‐DUX4 fusion transcript in four CIC‐rearranged sarcomas, indicating that at least one of the probes is working.